title: Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
abstract: A requisite step for canonical Hedgehog (Hh) pathway activation by Sonic Hedgehog (Shh) ligand is accumulation of Smoothened (Smo) to the primary cilium (PC). Activation of the Hh pathway has been implicated in a broad range of cancers, and several Smo antagonists are being assessed clinically, one of which is approved for the treatment of advanced basal cell carcinoma. Recent reports demonstrate that various Smo antagonists differentially impact Smo localization to the PC while still exerting inhibitory activity. In contrast to other synthetic small molecule Smo antagonists, the natural product cyclopamine binds to and promotes ciliary accumulation of Smo and "primes" cells for Hh pathway hyper-responsiveness after compound withdrawal. We compared the properties of IPI-926, a semi-synthetic cyclopamine analog, to cyclopamine with regard to potency, ciliary Smo accumulation, and Hh pathway activity after compound withdrawal. Like cyclopamine, IPI-926 promoted accumulation of Smo to the PC. However, in contrast to cyclopamine, IPI-926 treatment did not prime cells for hyper-responsiveness to Shh stimulation after compound withdrawal, but instead demonstrated continuous inhibition of signaling. By comparing the levels of drug-induced ciliary Smo accumulation with the degree of Hh pathway activity after compound withdrawal, we propose that a critical threshold of ciliary Smo is necessary for "priming" activity to occur. This "priming" appears achievable with cyclopamine, but not IPI-926, and is cell-line dependent. Additionally, IPI-926 activity was evaluated in a murine tumor xenograft model and a pharmacokinetic/pharmacodynamic relationship was examined to assess for in vivo evidence of Hh pathway hyper-responsiveness. Plasma concentrations of IPI-926 correlated with the degree and duration of Hh pathway suppression, and pathway activity did not exceed baseline levels out to 96 hours post dose. The overall findings suggest that IPI-926 possesses unique biophysical and pharmacological properties that result in Hh pathway inhibition in a manner that differentiates it from cyclopamine.
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Marisa O
authors.initials: MO
authors.lastname: Peluso
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Veronica T
authors.initials: VT
authors.lastname: Campbell
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Harari
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Thomas T
authors.initials: TT
authors.lastname: Tibbitts
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Proctor
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Nigel
authors.initials: N
authors.lastname: Whitebread
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: James M
authors.initials: JM
authors.lastname: Conley
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Kerry F
authors.initials: KF
authors.lastname: White
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Jeffery L
authors.initials: JL
authors.lastname: Kutok
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Read
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Karen
authors.initials: K
authors.lastname: McGovern
authors.affiliation: Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America.
authors.forename: Kerrie L
authors.initials: KL
authors.lastname: Faia
mesh_terms: D000818:Animals; D002460:Cell Line; D002923:Cilia / Q000187:drug effects / Q000378:metabolism*; D053823:Hedgehog Proteins / Q000378:metabolism*; D006801:Humans; D051379:Mice; D041681:NIH 3T3 Cells; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D000072086:Smoothened Receptor; D014704:Veratrum Alkaloids / Q000494:pharmacology*
chemical_list: D053823:Hedgehog Proteins; C541444:IPI-926; D043562:Receptors, G-Protein-Coupled; C491023:SMO protein, human; C491022:Smo protein, mouse; D000072086:Smoothened Receptor; D014704:Veratrum Alkaloids